Legal Representation
Attorney
Lynn A. Sullivan
USPTO Deadlines
Application History
23 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Sep 30, 2013 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Sep 30, 2013 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Feb 26, 2013 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Jan 14, 2013 | CHPB | I | CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED | Loading... |
Jan 7, 2013 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
Jan 1, 2013 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Jan 1, 2013 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Dec 15, 2012 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
Dec 12, 2012 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Nov 29, 2012 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Nov 28, 2012 | ALIE | A | ASSIGNED TO LIE | Loading... |
Nov 28, 2012 | DMCC | I | DATA MODIFICATION COMPLETED | Loading... |
Nov 28, 2012 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Nov 26, 2012 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Nov 15, 2012 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Nov 14, 2012 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Nov 14, 2012 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
May 24, 2012 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
May 24, 2012 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
May 24, 2012 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
May 18, 2012 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Feb 14, 2012 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Feb 11, 2012 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Scientific research for others for the development of antibodies for binding to one or more disease targets for the diagnosis, prevention of treatment of autoimmune and other serious medical diseases; scientific product development for others, namely, humanization and optimization of antibodies for binding to one or more disease targets for the diagnosis, prevention or treatment of autoimmune and other serious medical diseases
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
042